Immune Response Remune, Unimed NTZ cleared for expanded access by FDA.
Executive Summary
IMMUNE RESPONSE REMUNE EXPANDED ACCESS PROGRAM TO ADD 2,000 PATIENTS with CD4 cell counts under 300 or above 550, the company said Oct. 15. FDA authorized expanded access for the gp120-depleted inactivated "Salk" HIV-1 immunogen to individuals who cannot participate in the Phase III trial, which was limited to patients with CD4 cell counts between 300 and 550.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth